Tandem Diabetes Care, Inc. TNDM
18.13 USD -0.64 (-3.44%)
Nov 12, 2026, 2:24 PM EST
17.77 Day range 19.20
12.26 52-week range 29.65
- YTD
- -17.54%
- 1 year
- +0.36%
News
businesswire.com Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of Health Canada approval…
marketbeat.com What Tandem Diabetes Care (TNDM) Said on Its Q3 Earnings Call Tandem Diabetes Care NASDAQ: TNDM reported 14% revenue growth in the third quarter of 2026, as higher pump shipments, pharmacy pricing and international sales helped lift gross margin. The company…
benzinga.com Barclays Maintains Equal-Weight on Tandem Diabetes Care, Raises Price Target to $20 Barclays analyst Christopher Pasquale maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Equal-Weight and raises the price target from $18 to $20.
benzinga.com Wells Fargo Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $25 Wells Fargo analyst Larry Biegelsen maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and lowers the price target from $27 to $25.
seekingalpha.com Tandem Diabetes Care, Inc. (TNDM) Q3 2026 Earnings Call Transcript Tandem Diabetes Care, Inc. (TNDM) Q3 2026 Earnings Call Transcript
zacks.com Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare…
zacks.com Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Beats Revenue Estimates Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.31 per share a year ago.
benzinga.com Tandem Diabetes Care Q3 2026 Earnings Call Transcript Tandem Diabetes Care (NASDAQ:TNDM) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…- benzinga.com Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.072B Est Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.072 billion estimate.
businesswire.com Tandem Diabetes Care Names Jeannette Bankes as President and Chief Executive Officer SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Jeannette Bankes named President and CEO of Tandem Diabetes Care in planned transition as John Sheridan Retires After Over a Decade of Service.
benzinga.com Tandem Diabetes Care Q3 EPS $(0.10) Beats $(0.25) Estimate, Sales $283.690M Beat $265.922M Estimate Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.25) by 60 percent. This is a 67.74 percent increase over losses of…
businesswire.com Tandem Diabetes Care Announces Third Quarter 2026 Financial Results SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter…
benzinga.com Tandem Diabetes Care Q2 2026 Earnings Call Transcript Tandem Diabetes Care (NASDAQ:TNDM) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga…- benzinga.com Barclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18 Barclays analyst Christopher Pasquale initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Equal-Weight rating and announces Price Target of $18.
benzinga.com Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20 Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.
benzinga.com FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
benzinga.com William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating William Blair analyst Steven Lichtman initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform rating.
benzinga.com Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth potential in the insulin pump market.
benzinga.com Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading…
benzinga.com Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $21 Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target from $17 to $21.
benzinga.com RBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $26 RBC Capital analyst Kendall Au maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and lowers the price target from $30 to $26.
benzinga.com Tandem Diabetes Care Q2 EPS $(0.31) Beats $(0.32) Estimate, Sales $254.560M Miss $254.978M Estimate Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.32) by 3.13 percent. This is a 60.26 percent increase over losses of…- benzinga.com Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.074B Est Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.074 billion estimate.
- benzinga.com Mizuho Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20 Mizuho analyst Anthony Petrone maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.
benzinga.com This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page for full coverage.- benzinga.com Deutsche Bank Initiates Coverage On Tandem Diabetes Care with Hold Rating, Announces Price Target of $15.5 Deutsche Bank analyst Kieran Ryan initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Hold rating and announces Price Target of $15.5.
benzinga.com Tandem Diabetes Care Receives CE Mark For Expanded Indications Of Its Automated Insulin Delivery Systems In Europe Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of CE mark for expanded indications of its automated insulin delivery…- benzinga.com Wells Fargo Upgrades Tandem Diabetes Care to Overweight, Raises Price Target to $27 Wells Fargo analyst Larry Biegelsen upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Equal-Weight to Overweight and raises the price target from $21 to $27.
- benzinga.com Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $17 Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $22 to $17.
- benzinga.com B of A Securities Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25 B of A Securities analyst Travis Steed maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $35 to $25.
benzinga.com This Southwest Gas Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts change outlook on top names. Check their ratings & price targets for AVEX, ALMR, TNDM, SWX, KLRA. See what they think of SWX stock.- benzinga.com Truist Securities Reiterates Buy on Tandem Diabetes Care, Lowers Price Target to $31 Truist Securities analyst Richard Newitter reiterates Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and lowers the price target from $35 to $31.
- benzinga.com Barclays Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $55 Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and lowers the price target from $56 to $55.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.076B Est. Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.076 billion estimate.
- benzinga.com Tandem Diabetes Care Q1 Adj. EPS $(0.30) Beats $(0.45) Estimate, Sales $247.221M Beat $241.125M Estimate. Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.45) by 33.33 percent. This is a 54.55 percent increase over losses…
benzinga.com FDA Flags High-Risk Recall For Tandem Diabetes Mobi Pumps FDA flags Class I recall for Tandem Mobi insulin pumps tied to software glitch that may halt insulin delivery, with four injuries reported.- benzinga.com TD Cowen Maintains Buy on Tandem Diabetes Care, Raises Price Target to $28 TD Cowen analyst Mathew Blackman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target from $25 to $28.
- benzinga.com Goldman Sachs Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25 Goldman Sachs analyst David Roman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $28 to $25.
benzinga.com Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves MiniMed shows improved pipeline and valuation upside as insulin pump adoption grows despite rising competition and past share losses.
benzinga.com Nvidia To $323? Here Are 10 Top Analyst Forecasts For Thursday Analyst ratings changed for top Wall Street names. Morgan Stanley cut Carnival Corp price target, Raymond James raised NVIDIA Corp's target and more.
benzinga.com This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday Top Wall Street analysts upgraded Carnival Corp, Tandem Diabetes Care, and Union Pacific Corp. Analysts see potential in UNP stock.- benzinga.com Truist Securities Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $35 Truist Securities analyst Richard Newitter upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and raises the price target from $27 to $35.
benzinga.com Bullish Call On Tandem Diabetes Signals Long-Term Growth Confidence Piper Sandler upgrades Tandem Diabetes, citing pharmacy shift, international growth, and Mobi launch as key revenue drivers.
benzinga.com Semtech To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85, Mizuho cut Canadian Solar's PT to $19, Piper Sandler raised Tandem Diabetes' PT to $33, Stifel increased…
benzinga.com This Lemonade Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Top Wall Street analysts changed their outlook on top names. Upgrades include LMND, CSIQ, TNDM, ICHR, and NSA. See what analysts say about LMND.- benzinga.com Piper Sandler Upgrades Tandem Diabetes Care to Overweight, Raises Price Target to $33 Piper Sandler analyst Matt O'Brien upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Neutral to Overweight and raises the price target from $21 to $33.
benzinga.com Morgan Stanley Maintains Equal-Weight on Tandem Diabetes Care, Raises Price Target to $25 Morgan Stanley analyst Patrick Wood maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Equal-Weight and raises the price target from $23 to $25.- benzinga.com Lake Street Upgrades Tandem Diabetes Care to Buy, Announces $50 Price Target Lake Street analyst Frank Takkinen upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and announces $50 price target.
- benzinga.com Truist Securities Reiterates Hold on Tandem Diabetes Care, Raises Price Target to $27 Truist Securities analyst Richard Newitter reiterates Tandem Diabetes Care (NASDAQ:TNDM) with a Hold and raises the price target from $24 to $27.